Table of Contents
- Key safety points
- Overview
- Forms and Bioavailability
- Evidence for Benefits
- Recommended Dosing
- Safety and Side Effects
- Drug Interactions
- Dietary Sources
- References
Key safety points
- If you take warfarin or another vitamin K antagonist, keep your vitamin K intake from food and supplements steady [1], and do not start, stop or change a vitamin K supplement without your anticoagulation clinic [38].
- Vitamin K intake is not expected to change the effect of newer blood thinners such as apixaban, rivaroxaban and dabigatran [45, 46, 55].
- Orlistat taken with warfarin might cause a significant increase in prothrombin time, and orlistat, bile acid sequestrants and long courses of antibiotics can lower vitamin K status [1, 50].
- MK-7 is often made from natto, a fermented soybean food, so people with a soy allergy should check the source on the label [1, 6].
- Vitamin K3 (menadione) damaged liver cells in laboratory studies and is no longer used in supplements [1].
- There is no upper limit for vitamin K and no reported harm from food or supplements, but Brad advises against taking more than about 90 to 120 mcg [1, 55].
- In trials, K1 and MK-7 supplements caused no more side effects than placebo; drug-level doses of MK-4 may cause stomach discomfort and diarrhea [20, 31, 57].
1. Overview
Vitamin K is the generic name for a family of fat-soluble compounds with a common chemical structure of 2-methyl-1,4-naphthoquinone [1].
The designation "K" comes from the German word "Koagulation," because Danish biochemist Henrik Dam discovered it in the 1920s as an anti-hemorrhagic factor essential for blood clotting [2]. In 1943, Dam and American biochemist Edward Doisy shared the Nobel Prize in Physiology or Medicine for discovering vitamin K and elucidating its chemical structure [2].
The vitamin K family includes two naturally occurring forms [1]:
- Vitamin K1 (phylloquinone): The main plant form, present mostly in green leafy vegetables and also in vegetable oils and some fruits. Phytonadione is a man-made form of K1 [1].
- Vitamin K2 (menaquinones): A group of compounds, mostly of bacterial origin, designated MK-4 through MK-13 based on the length of their side chains. MK-4, MK-7, and MK-9 are the most well-studied. Menaquinones are present in modest amounts in various animal-based and fermented foods. Gut bacteria also produce menaquinones, though it is unclear how much this contributes to the body's vitamin K [1].
A third form, menadione, sometimes called vitamin K3, is synthetic. It was shown to damage liver cells in laboratory studies conducted during the 1980s and 1990s, so it is no longer used in dietary supplements or fortified foods [1].
Biochemical Functions
Vitamin K functions as a coenzyme for vitamin K-dependent carboxylase, an enzyme required for the synthesis of proteins involved in blood clotting and bone metabolism [1]. This enzyme, gamma-glutamyl carboxylase (GGCX), converts glutamate (Glu) residues to gamma-carboxyglutamate (Gla) residues, a change required for the activity of vitamin K-dependent proteins [4]. The reaction uses reduced vitamin K, CO2, and O2 as co-substrates and converts vitamin K to vitamin K epoxide [4]. The epoxide must be recycled to vitamin K before it can be reused, a reaction catalyzed by vitamin K epoxide reductase (VKOR) [4, 5]. This recycling is known as the vitamin K cycle [4].
Key vitamin K-dependent proteins include:
- Coagulation factors: Vitamin K is a cofactor in the production of blood coagulation factors in the liver [6]. Prothrombin (clotting factor II) is a vitamin K-dependent protein in plasma that is directly involved in blood clotting [1].
- Osteocalcin: A vitamin K-dependent protein present in bone that may be involved in bone mineralization or turnover [1]. In humans, the percentage of circulating osteocalcin that is not carboxylated (percent ucOC) is used as a biomarker of vitamin K status [7].
- Matrix Gla protein (MGP): Present in vascular smooth muscle, bone, and cartilage. MGP is the focus of considerable research because it might help reduce abnormal calcification [1, 8]. Some studies measure dp-ucMGP, the uncarboxylated form of MGP in blood, which rises when vitamin K status is low [28, 35].
Absorption, Transport, and Metabolism
Like other fat-soluble vitamins, ingested vitamin K is incorporated into mixed micelles via the action of bile and pancreatic enzymes, and it is absorbed by enterocytes of the small intestine [1, 9]. Because vitamin K is fat soluble, eating vegetables with some fat improves absorption of their vitamin K [1].
Vitamin K is then incorporated into chylomicrons, secreted into the lymphatic capillaries, transported to the liver, and repackaged into very low-density lipoproteins [1, 9]. It is present in the liver and other body tissues, including the brain, heart, pancreas, and bone [1, 10].
MK-7 has a much longer half-life than K1, which gives more stable serum levels and 7- to 8-fold higher accumulation during prolonged intake [6]. At nutritional doses, MK-4 was not detectable in the blood of healthy women after a single dose or a week of daily doses, while MK-7 was well absorbed and raised blood levels [56].
The body converts phylloquinone to MK-4 through a process that does not involve bacterial action [1].
Vitamin K is rapidly metabolized and excreted. Based on phylloquinone measurements, the body retains only about 30-40% of an oral physiological dose, while about 20% is excreted in the urine and 40-50% in the feces via bile [1]. This rapid metabolism accounts for vitamin K's relatively low blood levels and tissue stores compared with the other fat-soluble vitamins [1, 11].
Vitamin K Status Assessment
Vitamin K status is not routinely assessed except in people who take anticoagulants or have bleeding disorders. The only clinically significant indicator is prothrombin time, the time it takes for blood to clot [1].
In healthy people, fasting plasma phylloquinone concentrations have been reported to range from 0.29 to 2.64 nmol/L [1]. People slightly below this range have no clinical signs of deficiency, possibly because plasma phylloquinone does not measure the menaquinones from the diet and the large bowel [1, 12].
2. Forms and Bioavailability
Vitamin K1 (Phylloquinone)
Phylloquinone is the main dietary form of vitamin K and is present primarily in green leafy vegetables [1].
Phylloquinone in plant foods is tightly bound to chloroplasts, so it is less bioavailable than that from oils or dietary supplements. For example, the body absorbs only 4-17% as much phylloquinone from spinach as from a tablet [1]. Eating vegetables with some fat improves absorption, but the amount absorbed is still lower than from oils [1].
The absorption rate of phylloquinone in its free form is about 80%, but its absorption rate from foods is much lower [1].
Vitamin K2 as MK-7 (Menaquinone-7)
Natto, a Japanese food made from fermented soybeans, has high amounts of menaquinones [1], and the MK-7 in supplements is often derived from natto [6].
In a study by Schurgers et al. (2007), MK-7 stayed in the blood much longer than K1 and induced more complete carboxylation of osteocalcin [6].
According to the NIH fact sheet, limited research suggests that long-chain menaquinones may have higher absorption rates than phylloquinone from green vegetables [1].
From the MicroVitamin range
MicroVitamin includes 90 mcg of vitamin K2 as MK-7, an encapsulated form that stays in the blood much longer than vitamin K1. Vitamin K2 activates osteocalcin, which helps direct calcium to bone, alongside vitamin D3 (1,000 IU) and boron (3 mg). If you take a blood thinner such as warfarin, talk to your doctor first, because vitamin K2 can affect clotting. MicroVitamin. See MicroVitamin
Vitamin K2 as MK-4 (Menaquinone-4)
MK-4 occurs in small amounts in meat and eggs [1]. Menatetrenone, the MK-4 used as an osteoporosis drug in Japan, is synthetic [57]. MK-4 is unique in that the body makes it from phylloquinone through a conversion process that does not involve bacterial action [1]. Laboratory work has identified UBIAD1 as a human MK-4 biosynthetic enzyme [13].
At nutritional doses, MK-4 taken by mouth did not raise blood MK-4 levels in one study [56]. At pharmacological doses it is used to treat osteoporosis in parts of Asia (see Bone Health).
Other Menaquinone Forms
Almost all menaquinones, in particular the long-chain forms, are produced by bacteria in the human gut [1, 14]. Fermented foods such as cheese also contain menaquinones, but their forms and amounts likely vary with the bacterial strains used and the fermentation conditions [1]. Data on the bioavailability of different forms of vitamin K from food are very limited [1].
Comparative Pharmacokinetics
| Property | K1 (Phylloquinone) | K2 as MK-4 | K2 as MK-7 |
|---|---|---|---|
| Half-life | Shorter than MK-7 | No data | Longer; 7- to 8-fold higher serum accumulation during prolonged intake |
| Absorption | Free form about 80%; much lower from foods | Not detectable in blood at nutritional doses in one study [56] | Well absorbed as a supplement |
In small trials in postmenopausal women with osteoporosis, mostly in Japan, a drug dose of MK-4 (45,000 mcg a day) modestly raised spine density and lowered fracture rates [57]; MK-7 trials have given mixed results [24, 61, 62].
Fat-Soluble Vitamin Interactions
A laboratory study in intestinal cells found that vitamins D, E, and K competed with each other for uptake, and vitamin A also lowered uptake of the others [15]. Vitamin E may interfere with vitamin K activity, especially blood clotting, and vitamin E supplements cause bleeding in some people for reasons that are not understood [58].
3. Evidence for Benefits
Bone Health
Overview of the Vitamin K–Bone Connection
In observational studies, postmenopausal women with low bone density had lower blood vitamin K levels [16], and people with low vitamin K intake had more hip fractures [17, 73]. Vitamin K is required for the carboxylation of osteocalcin, one of the main proteins in bone, so deficiency could reduce bone mineralization [1]. According to the NIH fact sheet, some research indicates that high serum levels of undercarboxylated osteocalcin are associated with lower bone mineral density (BMD) [1]. However, it is unclear whether supplementing with any form of vitamin K reduces the risk of osteoporosis, and trial results have been mixed [1].
A systematic review and meta-analysis by Cockayne et al. included 13 randomized controlled trials. Most were conducted in Japan in postmenopausal women, and trial duration ranged from 6 to 36 months. Twelve of the 13 trials found that supplementation with either phytonadione (K1) or MK-4 improved bone mineral density. Seven trials had fracture data for meta-analysis, and all of them used MK-4 at either 15 mg/day (1 trial) or 45 mg/day (6 trials) [1]. MK-4 supplementation significantly reduced rates of hip fractures, vertebral fractures, and all nonvertebral fractures [1, 18].
However, later trials have produced more mixed results, particularly when participants also received calcium and vitamin D [1].
Vitamin K1 Bone Trials
Braam et al. (2003): In a placebo-controlled trial of 181 healthy postmenopausal women aged 50 to 60 years, adding daily vitamin K1 (1,000 mcg) to calcium, magnesium, zinc and vitamin D (320 IU) for three years reduced bone loss at the femoral neck compared with placebo or the same minerals and vitamin D alone; the lumbar spine showed no difference [59].
Booth et al. (2008): In 452 men and women aged 60 to 80 who took daily vitamin D (400 IU) and calcium (600 mg), a multivitamin with 500 mcg of K1 for three years made no difference to bone density at the hip, spine or whole body compared with the same multivitamin without K1 [60].
Binkley et al.: In one trial, 381 postmenopausal women received either 1 mg K1, 45 mg MK-4, or placebo daily for 12 months, all with calcium and vitamin D supplements [1]. Both vitamin K groups had significantly lower undercarboxylated osteocalcin, but there were no significant differences in BMD at the lumbar spine or proximal femur among any groups [1, 19].
Cheung et al. (2008): In a trial of 440 postmenopausal women with osteopenia, 5,000 mcg of K1 a day did not change bone density compared with placebo over two to four years [20]. Fewer women taking K1 had clinical fractures (nine versus 20), but fractures were a secondary outcome the trial was not powered to examine [20]. Vitamin K was well tolerated, with no significant differences in adverse effects [20].
Crohn's disease: Vitamin K deficiency is common in inflammatory bowel disease, more so in Crohn's disease than in ulcerative colitis, but its link with bone disease is controversial [21].
Vitamin K2 (MK-4) Bone Trials
Eight randomized trials, six in Japan and one each in Indonesia and China, gave postmenopausal women with osteoporosis 45,000 mcg of MK-4 a day for one to three years. In these mostly small trials, MK-4 alone modestly raised spine bone density and lowered fracture rates, mainly of the spine, and no toxic effects of this dose have been reported [57]. A Japanese dose-finding study compared daily doses of 15, 45, 90, and 135 mg and found 45 mg the lowest dose that improved bone measures [22, 57].
In Japan and other parts of Asia, a pharmacological dose of MK-4 (45 mg) is used as a treatment for osteoporosis [1]. The European Food Safety Authority has approved a health claim stating that "a cause and effect relationship has been established between the dietary intake of vitamin K and the maintenance of normal bone" [1, 23]. The U.S. FDA has not authorized a health claim for vitamin K [1].
Vitamin K2 (MK-7) Bone Trials
Knapen et al. (2013): Healthy postmenopausal women who took 180 mcg of MK-7 a day for three years kept more bone at the lumbar spine and femoral neck, by both mineral content and density, than those taking placebo; the total hip showed no difference [24].
The trial enrolled 244 healthy postmenopausal women, who took placebo or MK-7 for 3 years [24]. Bone strength was also favorably affected [24].
Ronn et al. (2020): In 142 postmenopausal women with osteopenia, all taking vitamin D3 (1,520 IU) and calcium (800 mg) a day, adding 375 mcg of MK-7 for three years made no difference to bone density, which fell at every site in both groups [61]. Bone turnover markers and bone microarchitecture also changed alike with MK-7 and placebo [61].
Zhang et al. (2020): A one-year trial in China randomized 311 men and postmenopausal women aged 50 to 75 years to placebo, MK-7 at 50 mcg/day or 90 mcg/day, or 90 mcg/day with calcium (500 mg) and vitamin D (400 IU). Loss of density at the femoral neck was smaller in postmenopausal women given 90 mcg/day than with placebo, but there was no effect in men, and adding vitamin D and calcium brought no extra benefit [62].
Summary of Bone Evidence
Vitamin K is involved in bone metabolism through osteocalcin carboxylation, but it is unclear whether supplementation with any form of vitamin K reduces the risk of osteoporosis [1]. Clinical trials do not provide overall support for the idea that vitamin K supplementation of the general population will reduce bone loss or fracture risk [7].
Giving vitamin D and/or calcium along with vitamin K could partly explain why some studies have found a bone benefit and others have not [1].
Cardiovascular Health
Observational Evidence
In Dutch observational studies, people who ate more vitamin K2 had less coronary calcification and were less likely to die of coronary heart disease [25, 26].
In the Rotterdam Study, a prospective cohort of 4,807 men and women age 55 years and older from the Netherlands, menaquinone intake was inversely associated with severe aortic calcification [1].
Participants in this study with menaquinone intakes in the upper tertile (>32.7 mcg/day) had a 57% lower risk of coronary heart disease mortality than those in the lower tertile (<21.6 mcg/day) [1]. Phylloquinone (K1) intake had no effect on any outcome [1, 25].
A separate observational study in the Netherlands included 564 postmenopausal women [1]. In this study, dietary menaquinone (but not phylloquinone) intake was inversely associated with coronary calcification [1, 26].
Vascular calcification is one of the risk factors for coronary heart disease because it reduces aortic and arterial elasticity [1, 27]. A hypothesis based on animal data suggests that inadequate vitamin K status leads to undercarboxylated MGP, which could increase vascular calcification and the risk of coronary heart disease. The full biological function of MGP is unclear [1].
MK-7 Cardiovascular Trials
The MK-7 trials below differ in who took part, the dose and what they measured. Two of them, and a subgroup of a third, found that coronary calcium scores rose more slowly with MK-7 (given with vitamin D in [69, 70]) in people who already had coronary calcification [64, 69, 70]:
Knapen et al. (2015): In a double-blind trial of 244 healthy postmenopausal women, 180 mcg of MK-7 (MenaQ7) a day for three years lowered arterial stiffness compared with placebo, and the effect was larger in women whose arteries were stiffest at the start [28]. MK-7 lowered dp-ucMGP by 50% but did not change blood markers of inflammation or endothelial dysfunction [28].
de Vries et al. (2025): In 165 women with low vitamin K status who took MK-7 at that dose or placebo for one year, MK-7 attenuated vascular stiffness in the 87 post-menopausal women, measured as Young's modulus (adjusted p = 0.035) [63]. This was a post hoc analysis, and Young's modulus was the only stiffness measure that differed: the other vascular measures, and all vascular measures in the 78 pre- or peri-menopausal women, did not differ significantly from placebo [63]. The supplement maker Gnosis by Lesaffre funded the study, and three of the authors were employed by Lesaffre [63].
Vossen et al. (2026): In a Dutch placebo-controlled trial, 180 people with coronary artery disease symptoms and calcium scores between 50 and 400 AU took 360 mcg of MK-7 or placebo daily for two years; calcium scores rose less with MK-7, and there were no significant adverse effects [64]. The number of soft, non-calcified plaques did not differ significantly between the groups [55].
Bartstra et al. (2021): In a pre-specified post hoc analysis of a six-month trial in 68 people with type 2 diabetes and cardiovascular disease, a daily dose of 360 mcg of vitamin K2 neither reduced the progression of arterial calcification nor slowed bone density loss compared with placebo [65].
Witham et al. (2020): In a double-blind trial in 159 adults with stage 3b or 4 chronic kidney disease, mean age 66, a year of 400 mcg of vitamin K2 a day did not improve pulse wave velocity, a measure of arterial stiffness, or blood pressure compared with placebo; an updated meta-analysis in the same paper found no effect of vitamin K on vascular stiffness or calcification [66].
Kurnatowska et al. (2015): In 42 people with stage 3 to 5 chronic kidney disease not on dialysis, carotid intima-media thickness (thickening of the artery wall) rose less over about 270 days with 90 mcg of MK-7 a day added to 400 IU of vitamin D daily than with the vitamin D alone, but coronary calcification did not differ significantly between the groups [67].
Diederichsen et al. (2022): In 365 men (mean age 71) with aortic valve calcification, 720 mcg of MK-7 plus 1,000 IU of vitamin D a day for two years lowered dp-ucMGP but did not slow the build-up of valve calcium or the narrowing of the valve compared with placebo [29]. Rates of valve surgery, cardiovascular events and death from any cause were similar in both groups [29].
Hasific et al. (2025): A substudy of the same trial found that two years of MK-7 plus vitamin D, despite lowering dp-ucMGP, had no effect on inflammation in the fat around the heart and coronary arteries or on blood markers of inflammation [68].
Hasific et al. (2023), subgroup analysis: Another analysis of the same trial, in 304 men without known ischemic heart disease, found no significant reduction in coronary calcium progression overall, but slower progression in those who started with CAC scores ≥400 AU [69]. Across the whole group, fewer people given supplements had a safety event, counted as a heart attack, a coronary revascularization or a death from any cause: 1.9% vs. 6.7% with placebo [69]. The trial authors called this a safety endpoint the study was not powered for, so it may be a chance finding [55].
Hasific et al. (2026): In 398 adults (median age 71) whose coronary calcium score was at least 400 AU, the score rose by a mean of 196 AU in two years with daily MK-7 (720 mcg) and vitamin D (1,000 IU), against 248 AU with placebo [70]. The volume of non-calcified plaque did not differ significantly between the groups [55, 70].
Vitamin K1 Cardiovascular Trials
Shea et al. (2009): In a three-year trial in 388 healthy older men and women, calcification progressed 6% less in those with existing coronary calcification who took a multivitamin with 500 mcg of K1 a day than in those given the multivitamin alone [1, 30]. Across all participants, there was no significant difference in coronary artery calcification between the groups [1, 30].
Bellinge et al. (2021): A post hoc analysis of a double-blind trial in Western Australia gave people with diabetes and existing coronary calcification 10 mg of K1 or placebo daily for three months. K1 lowered the odds of new calcifying lesions on PET scans in the coronary arteries (OR 0.35, 95% CI 0.16 to 0.78) and the aorta (OR 0.27, 95% CI 0.08 to 0.94) compared with placebo [71].
Summary of Cardiovascular Evidence
In observational studies, diets richer in K2 were associated with less coronary calcification and fewer deaths from coronary heart disease [1]. Most supplement trials found no overall effect on calcification or arterial stiffness [29, 30, 65, 66, 69]. The positive results came from narrower groups: calcium scores rose more slowly with MK-7 (given with vitamin D in [69, 70]) in people with symptoms of coronary artery disease and in people whose scores were already high, and with K1 in people who already had some calcification [30, 64, 69, 70]. That evidence is a slower rise in calcium score, not fewer heart attacks: no trial has shown that slowing coronary calcium reduces cardiovascular events, and soft plaque, the kind that can rupture, did not differ from placebo in the two dedicated trials [55].
Nocturnal Leg Cramps
In a placebo-controlled trial by Tan et al. (2024), 199 people in China aged 65 and older who had night cramps took 180 mcg of MK-7 or placebo daily for eight weeks [31]. With MK-7, cramps fell from a mean of 2.60 to 0.96 a week, while the placebo group averaged 3.63 a week, and cramps were also less severe and shorter [31]. The trial found no adverse events related to vitamin K2 [31].
How vitamin K might ease cramps is unclear; in one laboratory study, vitamin K3 relaxed mouse uterine muscle by acting on calcium and potassium channels [32].
Cancer
Observational evidence on vitamin K and cancer risk is mixed and does not establish cause and effect [33, 34]:
Nimptsch et al. (2010): In the EPIC-Heidelberg cohort in Germany, people who ate the most vitamin K2 (menaquinones), mostly from cheese, were less likely to die of cancer [33]. The link with lower cancer incidence was stronger in men than in women, mainly for prostate and lung cancers [33].
Wang et al. (2020): A larger U.S. cohort study found that higher dietary intake of K2 was associated with a higher risk of breast cancer (HR 1.26, 95% CI 1.05 to 1.52) and of death from breast cancer (HR 1.71, 95% CI 0.97 to 3.01) [34]. The study's authors said the findings would need to be replicated in other studies [34].
Neither study found a link with phylloquinone (K1) intake. Observational studies like these cannot show cause and effect [33, 34].
COVID-19
High blood levels of dp-ucMGP, which point to low vitamin K status, have been linked with COVID-19 and with poor outcomes in people in hospital [35, 72]:
Dofferhoff et al. (2020): Patients in hospital with COVID-19 had higher dp-ucMGP levels (indicating low vitamin K) than historic controls, and levels were higher still in patients with poor outcomes [72]. Higher dp-ucMGP was also linked with faster breakdown of elastic fibers [72].
Linneberg et al. (2020, preprint): In a cohort of 138 patients in hospital with COVID-19 and 138 population controls, average dp-ucMGP levels were higher in patients (1,022 pmol/L) than in controls (509 pmol/L) [35]. Those who died had levels of 1,445 pmol/L versus 877 pmol/L in those who survived [35]. After adjustment for sex and age, each doubling of dp-ucMGP was linked with a higher risk of death (HR 1.49, 95% CI 1.03 to 2.24), but in the published version this link weakened and was no longer statistically significant after adjustment for other health conditions [35].
The authors of the first study suggested that pneumonia may deplete vitamin K outside the liver, speeding elastic fiber damage and blood clots [72]. The authors of the second study said randomized trials would be needed to show whether vitamin K plays any role in the course of COVID-19 [35].
Blood Clotting
Bleeding is the classic sign of vitamin K deficiency, though it occurs only in severe cases [1]. Clinically significant vitamin K deficiency in adults is very rare and is usually limited to people with malabsorption disorders or those taking drugs that interfere with vitamin K metabolism [1].
An earlier guideline on warfarin-type drugs gave specific advice for managing INR results outside the target range [36]. Current guidance suggests against routine daily low-dose vitamin K supplements for people taking warfarin, because studies have not shown that they improve INR control or clinical outcomes [38]. A later American College of Chest Physicians guideline also addresses vitamin K supplementation for people on these drugs [37].
4. Recommended Dosing
Adequate Intakes
Data were insufficient to set an Estimated Average Requirement or Recommended Dietary Allowance (RDA) for vitamin K. Instead, the Food and Nutrition Board (FNB) at the Institute of Medicine set Adequate Intakes (AIs) based on vitamin K intakes in healthy population groups [1, 39]:
| Age/Sex Group | AI (mcg/day) |
|---|---|
| Birth to 6 months | 2.0 |
| 7-12 months | 2.5 |
| Children 1-3 years | 30 |
| Children 4-8 years | 55 |
| Children 9-13 years | 60 |
| Adolescents 14-18 years | 75 |
| Males 19+ years | 120 |
| Females 19+ years | 90 |
| Pregnancy (all ages) | 75-90 |
| Lactation (all ages) | 75-90 |
The European Food Safety Authority (EFSA) sets a different AI of 1 mcg per kg body weight per day, equating to approximately 70 mcg/day for average adults [40]. In Germany, the Deutsche Gesellschaft fur Ernahrung recommends 60-80 mcg/day for adults [41].
The FNB set no Tolerable Upper Intake Level (UL) because vitamin K has a low potential for toxicity [1]. The FNB stated that "no adverse effects associated with vitamin K consumption from food or supplements have been reported in humans or animals" [1].
Typical Intake in Populations
Data from the 2011-2012 National Health and Nutrition Examination Survey (NHANES) show that among U.S. children and teens age 2-19 years, the average daily vitamin K intake from foods is 66 mcg [1].
In adults age 20 and older, the average daily vitamin K intake from foods is 122 mcg for women and 138 mcg for men. When supplements are included, intake rises to 164 mcg for women and 182 mcg for men [1].
Some analyses of NHANES data from 2003-2006 and 2007-2010 found that only about one-third of the U.S. population had a vitamin K intake above the AI [1]. The significance of this is unclear because the AI is only an estimate of need, and reports of vitamin K deficiency in adults are very rare [1].
Doses Used in Clinical Research
Most trial doses are well above the AI, and they vary widely by form, from 50 mcg a day of MK-7 to 45 mg a day of MK-4 [57, 62]:
Vitamin K1 (phylloquinone):
- Bone health: 5,000 mcg/day, which did not improve bone density but may have reduced the risk of fractures over 2 to 4 years [20]
- Cardiovascular (calcification): 10 mg a day for three months in people with diabetes [71]
- Newborn prophylaxis: a single intramuscular dose of 0.5 to 1 mg at birth [1]
Vitamin K2 as MK-4:
- Bone health (pharmacological): 45 mg/day, the dose used to treat osteoporosis in Japan and other parts of Asia [1]
- Dose finding: in one Japanese study, 45,000 mcg a day was the lowest dose that improved bone measures, and 15,000 mcg was not enough [22, 57]
Vitamin K2 as MK-7:
- Bone health: 90-375 mcg/day [24, 61, 62]
- Cardiovascular health, lowest trial dose: 90 mcg of MK-7 with 400 IU of vitamin D daily over about 270 days in kidney disease [67]
- Cardiovascular health, highest trial dose: 720 mcg of MK-7 with vitamin D (1,000 IU) for two years [29, 70]
- Nocturnal leg cramps: 180 mcg every day for eight weeks [31]
Practical Dosing Considerations
Higher dietary vitamin K intake is associated with a lower risk of hip fractures, though not with higher bone density [73]. In one cohort of older men and women, those with the highest intake (a median of 254 mcg a day) had a lower risk of hip fracture than those with the lowest [73].
Brad advises against taking more than about 90 to 120 mcg a day. The 360 to 720 mcg doses that slowed coronary calcium are three to eight times the adequate intake [55].
Most multivitamin/mineral supplements provide less than 75% of the Daily Value for vitamin K [1].
Supplements containing only vitamin K, or vitamin K with a few other nutrients, have a wider range of doses, with some providing 4,050 mcg (5,063% of the DV) or another very high amount [1].
5. Safety and Side Effects
General Safety Profile
The Food and Nutrition Board reported no adverse effects from vitamin K in food or supplements in humans or animals [1]. No Tolerable Upper Intake Level has been established because of vitamin K's low potential for toxicity [1].
In small trials in Japan, Indonesia, and China, MK-4 was given at 45,000 mcg a day for one to three years, and no toxic effects of this dose have been reported [57]. Possible side effects of this drug-level dose are stomach discomfort and diarrhea, and it should not be used with warfarin [57].
Vitamin K3 (menadione) is different: it damaged liver cells in laboratory studies, so it is no longer used in dietary supplements or fortified foods [1].
Specific Safety Considerations
Soy allergy: The MK-7 in supplements is often derived from natto [6], which is made from fermented soybeans [1]. If you have a soy allergy, check the label or ask the maker about the source before starting.
Sleep concerns: Short sleep (less than 7 hours per night) has been linked with lower vitamin K intake from foods and supplements in adults aged 19 to 50 [42]. In that analysis of U.S. survey data, women with short sleep were more likely to have inadequate intake of several nutrients, including vitamin K [42].
Breast cancer: A U.S. cohort study found an association between higher dietary K2 intake and increased breast cancer risk [34]. An association does not prove cause and effect, and the authors said the findings need to be replicated [34].
Thyroid function: A review found little evidence that soy foods or soy isoflavones harm thyroid function in healthy people with adequate iodine, though soy foods may increase the dose of thyroid hormone that people with hypothyroidism need [43].
Newborn Vitamin K Prophylaxis
Newborns are vulnerable to vitamin K deficiency because of low placental transfer of phylloquinone, low clotting factor levels, and low vitamin K content of breast milk [1].
Vitamin K deficiency in the first weeks of life can cause vitamin K deficiency bleeding (VKDB), formerly known as classic hemorrhagic disease of the newborn [1]. Late VKDB occurs at 2-12 weeks of age, especially in exclusively breastfed infants, and can appear as sudden intracranial bleeding, which has a high mortality rate [1].
To prevent VKDB, the American Academy of Pediatrics recommends a single intramuscular dose of 0.5 to 1 mg of vitamin K1 at birth [1].
6. Drug Interactions
Warfarin and Vitamin K Antagonists
Vitamin K can have a serious and potentially dangerous interaction with warfarin (Coumadin) and similar anticoagulants such as phenprocoumon, acenocoumarol, and tioclomarol [1]. These drugs antagonize the activity of vitamin K, leading to depletion of vitamin K-dependent clotting factors [1]. Vitamin K epoxide reductase (VKOR), the enzyme that recycles vitamin K, is the target of warfarin [5].
Vitamin K may reduce the effectiveness of warfarin and similar drugs [1]. In a study of healthy volunteers taking acenocoumarol, a warfarin-like drug, MK-7 at 10 mcg a day lowered the INR to a clinically relevant degree in at least 40% of them, and the authors concluded that people on these drugs should avoid MK-7 supplements [44].
Guidance for warfarin care suggests against routine daily low-dose vitamin K supplements, and says a significant change in dietary vitamin K should prompt more frequent INR checks [38]. People on warfarin should check with their anticoagulation clinic or doctor before starting, stopping or changing a vitamin K supplement, because a change in vitamin K intake should prompt more frequent INR checks [38]. The authors of the MK-7 dose study advise that people on vitamin K antagonists avoid MK-7 supplements [44], and MK-4 at the drug dose used for osteoporosis is contraindicated with warfarin [57].
People taking warfarin should keep their vitamin K intake from food consistent, without large fluctuations [38]. NIH advises keeping vitamin K intake from both food and supplements consistent, because sudden changes can increase or decrease warfarin's anticoagulant effect [1].
Direct Oral Anticoagulants (DOACs)
Vitamin K intake is not expected to change the effect of newer blood thinners such as dabigatran (Pradaxa), rivaroxaban (Xarelto) and apixaban [45, 46, 55].
Antiplatelet Drugs
Aspirin and clopidogrel (Plavix) work differently from warfarin: they stop platelets from clumping rather than acting on vitamin K, so vitamin K is not expected to change their effect [47].
Antibiotics
Antibiotics can destroy vitamin K-producing bacteria in the gut, potentially decreasing vitamin K status. This effect might be more pronounced with cephalosporin antibiotics such as cefoperazone, because these antibiotics might also inhibit the action of vitamin K in the body [1, 14, 48]. Vitamin K supplements are usually not needed unless antibiotic use is prolonged (beyond several weeks) and accompanied by poor vitamin K intake [1, 48].
Bile Acid Sequestrants
Cholestyramine (Questran) and colestipol (Colestid) reduce cholesterol by preventing reabsorption of bile acids. They can also reduce absorption of vitamin K and other fat-soluble vitamins, although the clinical significance of this is not clear [1, 48]. Vitamin K status should be monitored in people taking these drugs, especially when they are used for many years [1, 49].
Orlistat
Orlistat (Alli, Xenical), a weight-loss drug, reduces the body's absorption of dietary fat and can also reduce absorption of fat-soluble vitamins such as vitamin K [1]. Combining orlistat with warfarin therapy might cause a significant increase in prothrombin time [1, 50]. Clinicians usually recommend that patients taking orlistat take a multivitamin supplement containing vitamin K [1, 51, 52].
Statins
A review by Okuyama and colleagues suggests that statins may inhibit the body's synthesis of vitamin K2 [53].
7. Dietary Sources
Vitamin K1 (Phylloquinone) — Plant Sources
Green leafy vegetables are major food sources of vitamin K1. The following values are from the NIH fact sheet, which draws on USDA data [1]:
| Food | Serving | Vitamin K1 (mcg) | % Daily Value* |
|---|---|---|---|
| Natto (fermented soybean) | 3 oz | 850 (as MK-7) | 708% |
| Collards, frozen, boiled | 1/2 cup | 530 | 442% |
| Turnip greens, frozen, boiled | 1/2 cup | 426 | 355% |
| Kale, raw | 1 cup | 113 | 94% |
| Spinach, raw | 1 cup | 145 | 121% |
| Broccoli, chopped, boiled | 1/2 cup | 110 | 92% |
| Soybeans, roasted | 1/2 cup | 43 | 36% |
| Carrot juice | 3/4 cup | 28 | 23% |
| Soybean oil | 1 tablespoon | 25 | 21% |
| Edamame, frozen, prepared | 1/2 cup | 21 | 18% |
| Pumpkin, canned | 1/2 cup | 20 | 17% |
| Pomegranate juice | 3/4 cup | 19 | 16% |
| Okra, raw | 1/2 cup | 16 | 13% |
| Pine nuts, dried | 1 oz | 15 | 13% |
| Blueberries, raw | 1/2 cup | 14 | 12% |
| Iceberg lettuce, raw | 1 cup | 14 | 12% |
| Canola oil | 1 tablespoon | 10 | 8% |
| Olive oil | 1 tablespoon | 8 | 7% |
*Daily Value = 120 mcg for adults and children age 4+.
The most common sources of vitamin K in the U.S. diet are spinach, broccoli, iceberg lettuce, and fats and oils (particularly soybean and canola oil) [1].
Vitamin K2 (Menaquinones) — Animal and Fermented Sources
Meat, dairy foods, and eggs contain low levels of phylloquinone but modest amounts of menaquinones [1, 54]. Dairy values below are total vitamin K, mostly as K2 [74]; meat and egg values are MK-4 from the NIH fact sheet [1].
| Food | Serving | Vitamin K (mcg) | Form |
|---|---|---|---|
| Soft cheeses (Brie, Camembert, mascarpone) | 100 g | ~506 | Mostly K2 |
| Blue cheese | 100 g | ~440 | Mostly K2 |
| Semi-soft cheeses (Gouda, Havarti, Swiss) | 100 g | ~289 | Mostly K2 |
| Hard cheeses (cheddar, parmesan) | 100 g | ~282 | Mostly K2 |
| Processed American cheese | 100 g | ~98 | Mostly K2 |
| Full-fat yogurt | 100 g | ~26.3 | Mostly K2 |
| Full-fat Greek yogurt | 100 g | ~28.2 | Mostly K2 |
| Full-fat milk | 100 g | ~38 | Mostly K2 |
| 2% milk | 100 g | ~19 | Mostly K2 |
| 1% milk | 100 g | ~12.9 | Mostly K2 |
| Fat-free milk | 100 g | ~7.7 | Mostly K2 |
| Low-fat kefir | 100 g | ~10.2 | Mostly K2 |
| Chicken breast, rotisserie | 3 oz | 13 | MK-4 |
| Egg, hard boiled | 1 large | 4 | MK-4 |
| Ground beef, broiled | 3 oz | 6 | MK-4 |
| Chicken liver, braised | 3 oz | 6 | MK-4 |
| Ham, roasted | 3 oz | 4 | MK-4 |
| Cheddar cheese | 1.5 oz | 4 | MK-4 |
Fu and colleagues measured vitamin K in U.S. dairy foods and found that the amount was proportional to fat content: products with reduced or no fat had about 5 to 22% as much vitamin K as their full-fat equivalents [74]. Cheddar is an example, with 49 mcg per 100 g in the reduced-fat version against 281 mcg in full-fat [74].
Impact of Gut Microbiota
Substantial quantities of long-chain menaquinones made by gut bacteria are present in the large bowel, but little is known about how they are absorbed and transported [1]. Although the amount of vitamin K the body obtains this way is unclear, the NIH fact sheet reports that experts believe these menaquinones satisfy at least some of the body's requirement for vitamin K [1, 14]. Antibiotics can reduce vitamin K status by destroying vitamin K-producing bacteria in the gut [1].
8. References
- National Institutes of Health, Office of Dietary Supplements. Vitamin K: Health Professional Fact Sheet. Updated March 29, 2021. NIH ODS
- Dam H. The discovery of vitamin K, its biological functions and therapeutical application. Nobel Lecture, 12 December 1946 (Nobel Prize in Physiology or Medicine 1943). Nobel Prize
- Stafford DW. The vitamin K cycle. J Thromb Haemost. 2005;3(8):1873-1878. PubMed
- Li T, Chang CY, Jin DY, et al. Identification of the gene for vitamin K epoxide reductase. Nature. 2004;427(6974):541-544. PubMed
- Schurgers LJ, Teunissen KJ, Hamulyak K, et al. Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood. 2007;109(8):3279-3283. PubMed
- Gundberg CM, Lian JB, Booth SL. Vitamin K-dependent carboxylation of osteocalcin: friend or foe? Adv Nutr. 2012;3(2):149-157. PubMed
- Schurgers LJ. Vitamin K: key vitamin in controlling vascular calcification in chronic kidney disease. Kidney Int. 2013;83(5):782-784. PubMed
- Shearer MJ, Fu X, Booth SL. Vitamin K nutrition, metabolism, and requirements: current concepts and future research. Adv Nutr. 2012;3(2):182-195. PubMed
- Ferland G. Vitamin K. In: Erdman JW, Macdonald IA, Zeisel SH, eds. Present Knowledge in Nutrition. 10th ed. Washington, DC: Wiley-Blackwell; 2012:230-247. https://doi.org/10.1002/9781119946045.ch15
- Shearer MJ, Newman P. Metabolism and cell biology of vitamin K. Thromb Haemost. 2008;100(4):530-547. PubMed
- Sadowski JA, Hood SJ, Dallal GE, et al. Phylloquinone in plasma from elderly and young adults: factors influencing its concentration. Am J Clin Nutr. 1989;50(1):100-108. PubMed
- Nakagawa K, et al. Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme. Nature. 2010;468(7320):117-121. PMID: 20953171. https://pubmed.ncbi.nlm.nih.gov/20953171/
- Conly JM, Stein K, Worobetz L, et al. The contribution of vitamin K2 (menaquinones) produced by the intestinal microflora to human nutritional requirements for vitamin K. Am J Gastroenterol. 1994;89(6):915-923. PubMed
- Goncalves A, Roi S, Nowicki M, et al. Fat-soluble vitamin intestinal absorption: absorption sites in the intestine and interactions for absorption. Food Chem. 2015;172:155-160. PubMed
- Kanai T, Takagi T, Masuhiro K, et al. Serum vitamin K level and bone mineral density in post-menopausal women. Int J Gynaecol Obstet. 1997;56(1):25-30. PubMed
- Feskanich D, Weber P, Willett WC, et al. Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr. 1999;69(1):74-79. PubMed
- Cockayne S, Adamson J, Lanham-New S, et al. Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166(12):1256-1261. PubMed
- Binkley N, Harke J, Krueger D, et al. Vitamin K treatment reduces undercarboxylated osteocalcin but does not alter bone turnover, density, or geometry in healthy postmenopausal North American women. J Bone Miner Res. 2009;24(6):983-991. PubMed
- Cheung AM, Tile L, Lee Y, et al. Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial. PLoS Med. 2008;5(10):e196. PubMed
- Weisshof R, Chermesh I. Micronutrient deficiencies in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care. 2015;18(6):576-581. PubMed
- Orimo H, Fujita T, Onomura T, Inoue T, Kushida K, Shiraki M. Clinical evaluation of soft capsule menatetrenone (Ea-0167) in the treatment of osteoporosis: late phase II dose study. J New Rem Clin. 1992;41:1249-1279 (in Japanese; no PubMed record; cited as the dose-finding study in Iwamoto J, Nutrients 2014;6(5):1971-1980, PMC4042573).
- European Food Safety Authority. Scientific opinion on the substantiation of health claims related to vitamin K and maintenance of bone. EFSA Journal. 2009;7:1228.
- Knapen MH, Drummen NE, Smit E, et al. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int. 2013;24(9):2499-2507. PubMed
- Geleijnse JM, Vermeer C, Grobbee DE, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr. 2004;134(11):3100-3105. PubMed
- Beulens JW, Bots ML, Atsma F, et al. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis. 2009;203(2):489-493. PubMed
- Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation. 2008;117(22):2938-2948. PubMed
- Knapen MH, Braam LA, Drummen NE, et al. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: a double-blind randomised clinical trial. Thromb Haemost. 2015;113(5):1135-1144. PubMed
- Diederichsen ACP, Lindholt JS, Möller S, et al. Vitamin K2 and D in patients with aortic valve calcification: a randomized double-blinded clinical trial. Circulation. 2022;145(18):1387-1397. PMID: 35465686. https://pubmed.ncbi.nlm.nih.gov/35465686/
- Shea MK, O'Donnell CJ, Hoffmann U, et al. Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am J Clin Nutr. 2009;89(6):1799-1807. PubMed
- Tan J, Zhu R, Li Y, et al. Vitamin K2 in managing nocturnal leg cramps: a randomized clinical trial. JAMA Intern Med. 2024;184(12):1443-1447. PMID: 39466236. https://pubmed.ncbi.nlm.nih.gov/39466236/
- Zhang XX, Lu LM, Wang L. Vitamin K3 inhibits mouse uterine contraction in vitro via interference with the calcium transfer and the potassium channels. Biochem Biophys Res Commun. 2016;476(4):393-399. PMID: 27237971. https://pubmed.ncbi.nlm.nih.gov/27237971/
- Nimptsch K, Rohrmann S, Kaaks R, et al. Dietary vitamin K intake in relation to cancer incidence and mortality: results from the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg). Am J Clin Nutr. 2010;91(5):1348-1358. PubMed
- Wang K, Wu Q, Li Z, et al. Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study. Clin Nutr. 2021;40(5):3370-3378. PMID: 33277073. https://pubmed.ncbi.nlm.nih.gov/33277073/
- Linneberg A, Kampmann FB, Israelsen SB, et al. The association of low vitamin K status with mortality in a cohort of 138 hospitalized patients with COVID-19. medRxiv. 2020 (preprint). Published in Nutrients. 2021;13(6):1985. PMID: 34207745. https://pubmed.ncbi.nlm.nih.gov/34207745/
- Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):160S-198S. PMID: 18574265. https://pubmed.ncbi.nlm.nih.gov/18574265/
- Holbrook A, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S-e184S. PMID: 22315259. https://pubmed.ncbi.nlm.nih.gov/22315259/
- Witt DM, Clark NP, Kaatz S, et al. Guidance for the practical management of warfarin therapy. J Thromb Thrombolysis. 2016;41(1):187-205. PMID: 26780746. https://pubmed.ncbi.nlm.nih.gov/26780746/
- Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academy Press; 2001. https://pubmed.ncbi.nlm.nih.gov/25057538/
- European Food Safety Authority. Dietary reference values for vitamin K. EFSA Journal. 2017;15(5):4780.
- Deutsche Gesellschaft fur Ernahrung (DGE). Vitamin K recommendations. DGE
- Ikonte CJ, Mun JG, Reider CA, et al. Micronutrient inadequacy in short sleep: analysis of the NHANES 2005-2016. Nutrients. 2019;11(10):2335. PMID: 31581561. https://pubmed.ncbi.nlm.nih.gov/31581561/
- Messina M, Redmond G. Effects of soy protein and soybean isoflavones on thyroid function in healthy adults and hypothyroid patients. Thyroid. 2006;16(3):249-258. PMID: 16571087. https://pubmed.ncbi.nlm.nih.gov/16571087/
- Theuwissen E, Teunissen KJ, Spronk HM, et al. Effect of low-dose supplements of menaquinone-7 (vitamin K2) on the stability of oral anticoagulant treatment: dose-response relationship in healthy volunteers. J Thromb Haemost. 2013;11(6):1085-1092. PMID: 23530987. https://pubmed.ncbi.nlm.nih.gov/23530987/
- Pradaxa (dabigatran) Prescribing Information. Boehringer Ingelheim; 2010.
- Xarelto (rivaroxaban) Prescribing Information. Janssen Pharmaceuticals; 2015.
- Plavix (clopidogrel) Prescribing Information. Bristol-Myers Squibb/Sanofi; 2015.
- Natural Medicines Comprehensive Database. Vitamin K. 2014.
- Vroonhof K, van Rijn HJ, van Hattum J. Vitamin K deficiency and bleeding after long-term use of cholestyramine. Neth J Med. 2003;61(1):19-21. PubMed
- MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. Ann Pharmacother. 2003;37(4):510-512. PubMed
- McDuffie JR, Calis KA, Booth SL, et al. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002;22(7):814-822. PubMed
- Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA. 1999;281(3):235-242. PubMed
- Okuyama H, Langsjoen PH, Hamazaki T, et al. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Expert Rev Clin Pharmacol. 2015;8(2):189-199. PMID: 25655639. https://pubmed.ncbi.nlm.nih.gov/25655639/
- Elder SJ, Haytowitz DB, Howe J, et al. Vitamin K contents of meat, dairy, and fast food in the U.S. diet. J Agric Food Chem. 2006;54(2):463-467. PubMed
- Stanfield B. Why aren't cardiologists prescribing vitamin K2? drstanfield.com. 3 September 2026. Brad's article
- Sato T, Schurgers LJ, Uenishi K. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. Nutr J. 2012;11:93. DOI: 10.1186/1475-2891-11-93. PMID: 23140417. https://pubmed.ncbi.nlm.nih.gov/23140417/
- Iwamoto J. Vitamin K2 therapy for postmenopausal osteoporosis. Nutrients. 2014;6(5):1971-1980. DOI: 10.3390/nu6051971. PMID: 24841104. https://pubmed.ncbi.nlm.nih.gov/24841104/
- Traber MG. Vitamin E and K interactions: a 50-year-old problem. Nutr Rev. 2008;66(11):624-629. DOI: 10.1111/j.1753-4887.2008.00123.x. PMID: 19019024. https://pubmed.ncbi.nlm.nih.gov/19019024/
- Braam LA, Knapen MH, Geusens P, et al. Vitamin K1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age. Calcif Tissue Int. 2003;73(1):21-26. DOI: 10.1007/s00223-002-2084-4. PMID: 14506950. https://pubmed.ncbi.nlm.nih.gov/14506950/
- Booth SL, Dallal G, Shea MK, et al. Effect of vitamin K supplementation on bone loss in elderly men and women. J Clin Endocrinol Metab. 2008;93(4):1217-1223. DOI: 10.1210/jc.2007-2490. PMID: 18252784. https://pubmed.ncbi.nlm.nih.gov/18252784/
- Rønn SH, Harsløf T, Oei L, et al. The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial. Osteoporos Int. 2021;32(1):185-191. DOI: 10.1007/s00198-020-05638-z. PMID: 33030563. https://pubmed.ncbi.nlm.nih.gov/33030563/
- Zhang Y, Liu Z, Duan L, et al. Effect of low-dose vitamin K2 supplementation on bone mineral density in middle-aged and elderly Chinese: a randomized controlled study. Calcif Tissue Int. 2020;106(5):476-485. DOI: 10.1007/s00223-020-00669-4. PMID: 32060566. https://pubmed.ncbi.nlm.nih.gov/32060566/
- de Vries F, Bittner R, Maresz K, et al. Effects of one-year menaquinone-7 supplementation on vascular stiffness and blood pressure in post-menopausal women. Nutrients. 2025;17(5):815. DOI: 10.3390/nu17050815. PMID: 40077685. https://pubmed.ncbi.nlm.nih.gov/40077685/
- Vossen LM, de Leeuw PW, Schurgers LJ, et al. Two years of menaquinone-7 supplementation and coronary artery calcification: a randomized clinical trial. JAMA Cardiol. 2026;11(8):719-726. DOI: 10.1001/jamacardio.2026.1279. PMID: 42268593. https://pubmed.ncbi.nlm.nih.gov/42268593/
- Bartstra JW, Draaisma F, Zwakenberg SR, et al. Six months vitamin K treatment does not affect systemic arterial calcification or bone mineral density in diabetes mellitus 2. Eur J Nutr. 2021;60(3):1691-1699. DOI: 10.1007/s00394-020-02412-z. PMID: 33068157. https://pubmed.ncbi.nlm.nih.gov/33068157/
- Witham MD, Lees JS, White M, et al. Vitamin K supplementation to improve vascular stiffness in CKD: the K4Kidneys randomized controlled trial. J Am Soc Nephrol. 2020;31(10):2434-2445. DOI: 10.1681/ASN.2020020225. PMID: 32817311. https://pubmed.ncbi.nlm.nih.gov/32817311/
- Kurnatowska I, Grzelak P, Masajtis-Zagajewska A, et al. Effect of vitamin K2 on progression of atherosclerosis and vascular calcification in nondialyzed patients with chronic kidney disease stages 3-5. Pol Arch Med Wewn. 2015;125(9):631-640. DOI: 10.20452/pamw.3041. PMID: 26176325. https://pubmed.ncbi.nlm.nih.gov/26176325/
- Hasific S, Ravn EJ, Rasmussen LM, et al. Effects of vitamin K2 and D3 supplementation on epicardial adipose tissue and systemic inflammation: a substudy of the AVADEC trial. Atherosclerosis. 2025;410:120540. DOI: 10.1016/j.atherosclerosis.2025.120540. PMID: 41100911. https://pubmed.ncbi.nlm.nih.gov/41100911/
- Hasific S, Oevrehus KA, Lindholt JS, et al. Effects of vitamin K2 and D supplementation on coronary artery disease in men: a RCT. JACC Adv. 2023;2(9):100643. DOI: 10.1016/j.jacadv.2023.100643. PMID: 38938724. https://pubmed.ncbi.nlm.nih.gov/38938724/
- Hasific S, Øvrehus KA, Mejldal A, et al. Vitamin K2 and D3 supplementation in patients with severe coronary artery calcification: the DANCODE trial. Circulation. 2026 (published online 28 August 2026). DOI: 10.1161/CIRCULATIONAHA.126.082363. PMID: 42661461. https://pubmed.ncbi.nlm.nih.gov/42661461/
- Bellinge JW, Francis RJ, Lee SC, et al. The effect of vitamin K1 on arterial calcification activity in subjects with diabetes mellitus: a post hoc analysis of a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2022;115(1):45-52. DOI: 10.1093/ajcn/nqab306. PMID: 34637494. https://pubmed.ncbi.nlm.nih.gov/34637494/
- Dofferhoff ASM, Piscaer I, Schurgers LJ, et al. Reduced vitamin K status as a potentially modifiable risk factor of severe coronavirus disease 2019. Clin Infect Dis. 2021;73(11):e4039-e4046. DOI: 10.1093/cid/ciaa1258. PMID: 32852539. https://pubmed.ncbi.nlm.nih.gov/32852539/
- Booth SL, Tucker KL, Chen H, et al. Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. Am J Clin Nutr. 2000;71(5):1201-1208. DOI: 10.1093/ajcn/71.5.1201. PMID: 10799384. https://pubmed.ncbi.nlm.nih.gov/10799384/
- Fu X, Harshman SG, Shen X, et al. Multiple vitamin K forms exist in dairy foods. Curr Dev Nutr. 2017;1(6):e000638. DOI: 10.3945/cdn.117.000638. PMID: 29955705. https://pubmed.ncbi.nlm.nih.gov/29955705/



